scholarly article | Q13442814 |
P819 | ADS bibcode | 2020NatCo..11.3736C |
P356 | DOI | 10.1038/S41467-020-17446-4 |
P698 | PubMed publication ID | 32719371 |
P50 | author | Abhishek N Prasad | Q56338678 |
Kevin Melody | Q57079485 | ||
Heinz Feldmann | Q60059378 | ||
Thomas W Geisbert | Q60061444 | ||
Larry Zeitlin | Q87766086 | ||
Krystle N Agans | Q88870564 | ||
Armand Sprecher | Q92709196 | ||
Robert W Cross | Q97905072 | ||
Joan B Geisbert | Q109874939 | ||
Karla A. Fenton | Q109875099 | ||
P2093 | author name string | Zachary A Bornholdt | |
Viktoriya Borisevich | |||
Daniel J Deer | |||
P2860 | cites work | Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates | Q21131585 |
Effective post-exposure treatment of Ebola infection | Q21131616 | ||
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) | Q28051937 | ||
Ebola and Marburg virus vaccines | Q30234637 | ||
Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. | Q33404944 | ||
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial | Q33818337 | ||
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses | Q33987611 | ||
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp | Q34426585 | ||
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates | Q34473079 | ||
EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain | Q34488551 | ||
Safety of recombinant VSV-Ebola virus vaccine vector in pigs | Q35229679 | ||
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection | Q35843254 | ||
Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection | Q36043284 | ||
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus | Q36239796 | ||
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody | Q39966889 | ||
Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona | Q40093846 | ||
Two-mAb cocktail protects macaques against the Makona variant of Ebola virus | Q40114600 | ||
mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms | Q40231241 | ||
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections | Q44089771 | ||
Post-exposure treatments for Ebola and Marburg virus infections | Q47548534 | ||
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates | Q56766240 | ||
Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77 | Q59794597 | ||
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection | Q64359231 | ||
A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates | Q64360457 | ||
New treatments for Ebola virus disease | Q93160757 | ||
P433 | issue | 1 | |
P921 | main subject | VSV-EBOV | Q18085856 |
P304 | page(s) | 3736 | |
P577 | publication date | 2020-07-27 | |
P1433 | published in | Nature Communications | Q573880 |
P1476 | title | Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment | |
P478 | volume | 11 |